Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diclofenac Sodium Gel 3% vs Solaraze in Actinic Keratosis
NCT03826550Phase 3Completed
- Sponsor
- Encube Ethicals
- Start
- Jan 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diclofenac in actinic keratosis (AK) (3 arms), sponsored by Encube Ethicals. Primary endpoints: Proportion of patients in each treatment group with 100% clearance of all AK Lesions at Day 90 and Superiority of the test and reference products against the placebo at Day 90. Started Jan 2018; status: completed.
02
Drugs
diclofenac
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03826550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826550.